Quratis Inc. (KOSDAQ:348080)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,115.00
-55.00 (-4.70%)
At close: Dec 5, 2025
78.40%
Market Cap 91.19B
Revenue (ttm) 2.28B
Net Income (ttm) -24.09B
Shares Out 81.79M
EPS (ttm) -370.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 918,626
Average Volume 396,373
Open 1,193.00
Previous Close 1,170.00
Day's Range 1,115.00 - 1,240.00
52-Week Range 516.00 - 2,095.00
Beta -0.67
RSI 66.25
Earnings Date n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; dendritic cell-based cell therapy for indications, including cancer, autoimmune, and infectious diseases; and peptide nucleic acid-based antimicrobial agents. The company also offers drugs contract development and manufacturing services. Quratis Inc. was founded in 2016 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 348080
Full Company Profile

Financial Performance

In 2024, Quratis's revenue was 373.80 million, a decrease of -63.71% compared to the previous year's 1.03 billion. Losses were -26.27 billion, 54.6% more than in 2023.

Financial Statements

News

There is no news available yet.